The global Rheumatoid Arthritis mAbs market reached a value of around $11.5 billion in 2011, and is expected to reach a total value by 2018 of $15.7 billion. The global Rheumatoid Arthritis mAbs market sees most of its value come from the United States region, with a 50.5% share. By 2018 the United States is expected to have increased its share to over 62%. As the European and Japanese markets experience slow growth or even deflation, the US market is expected to become increasingly prominent as high year-on-year inflation rates for specialty pharmaceuticals in the region drive prices upwards.
In 2011, the three top-selling mAbs (Remicade, Humira and Enbrel) generated over $23 billion in sales. They are the first three mAbs to have been indicated for the treatment of RA, and have consistently held the top three spots in terms of sales from year to year, despite the approval of arguably more effective mAb products.
There does not appear to be a noticeable correlation between the relative therapeutic value of each of product and their annual sales. Historical sales data for Humira shows that it rapidly generated sales above $1 billion worldwide during the first few years after its approval for RA alone. Compared to current data relating to early sales growth of products marketed since 2008, which shows much more modest early sales, there is a trend towards a market in which new products struggle to achieve the same success as previous competitors.
The pipeline for the mAbs market in RA is strong, with a total of 94 products. The majority are in preclinical, Phase I and Phase II development, and a considerable number lie in Phase III clinical trials.
For more information on the Global Rheumatoid Arthritis mAbs market, please click here: Global Rheumatoid Arthritis mAbs market
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.